Furthermore, the selective inhibition of LSD1 function in L-TAMs could be a promising strategy to enhance cancer treatments and TAMs reprogramming from an anti-inflammatory to an anti-tumor phenotype, thereby paving the way for novel therapeutic interventions. The gene discussed is KDM1A; the disease is neoplasm.